This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
G5B Overzicht aandelen
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Global Blood Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$68.40 |
| 52 Week Hoogtepunt | US$70.48 |
| 52 Week Laag | US$20.83 |
| Bèta | 0.46 |
| 11 maand verandering | 2.18% |
| 3 maanden verandering | 110.88% |
| 1 Jaar Verandering | 212.76% |
| 33 jaar verandering | 62.86% |
| 5 jaar verandering | 144.90% |
| Verandering sinds IPO | 48.47% |
Recent nieuws en updates
Recent updates
Rendement voor aandeelhouders
| G5B | DE Biotechs | DE Markt | |
|---|---|---|---|
| 7D | -1.5% | -1.3% | 0.02% |
| 1Y | 212.8% | -11.5% | 19.6% |
Rendement versus industrie: G5B exceeded the German Biotechs industry which returned -9.2% over the past year.
Rendement versus markt: G5B exceeded the German Market which returned -24.5% over the past year.
Prijsvolatiliteit
| G5B volatility | |
|---|---|
| G5B Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: G5B's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: G5B's weekly volatility has increased from 12% to 17% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Global Blood Therapeutics, Inc. Samenvatting
| G5B fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €4.69b |
| Inkomsten(TTM) | -€327.07m |
| Inkomsten(TTM) | €238.22m |
19.7x
P/S-verhouding-14.3x
Koers/WinstverhoudingIs G5B overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| G5B resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$234.86m |
| Kosten van inkomsten | US$4.45m |
| Brutowinst | US$230.41m |
| Overige uitgaven | US$552.87m |
| Inkomsten | -US$322.46m |
Laatst gerapporteerde inkomsten
Jun 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -4.78 |
| Brutomarge | 98.10% |
| Nettowinstmarge | -137.30% |
| Schuld/Eigen Vermogen Verhouding | 491.7% |
Hoe presteerde G5B op de lange termijn?
Bekijk historische prestaties en vergelijking